Fig. 2
From: Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease
a Cost-effectiveness plane: incremental costs and incremental QALYs of CSF biomarker analysis. b Probability of each diagnostic strategy being the cost-effective alternative at various willingness-to-pay thresholds when all model input parameters are varied simultaneously. AD Alzheimer’s disease, BM Biomarker, CA Clinical assessment, MR Magnetic resonance, QALY Quality-adjusted life-year